5-(2,6-二氯苯基)环己烷-1,3-二酮 | 55579-74-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-(2,6-二氯苯基)环己烷-1,3-二酮
• 英文名称: 5-(2,6-dichlorophenyl)cyclohexane-1,3-dione
• CAS: 55579-74-3
• 化学式: C₁₂H₁₀Cl₂O₂
• 分子量: 257.116
• InChiKey: XFSFQUOJDRNZIT-UHFFFAOYSA-N

物化性质

• 沸点：
  377.4±42.0 °C(Predicted)
• 密度：
  1.371±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2914700090

反应信息

• 作为反应物：
  描述：

  5-(2,6-二氯苯基)环己烷-1,3-二酮 在 碘苯二乙酸 、 potassium carbonate 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 30.0h， 生成 C₂₁H₁₇Cl₃O₄S
  参考文献：
  名称：

  Optimization of 5-(2,6-dichlorophenyl)-3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase

  摘要：

  Optimization of 5-(2,6-dichlorophenyl)-3-hydroxy-2-mercaptocyclohex-2-enone using structure-based design strategies resulted in inhibitors with considerable improvement in biochemical potency against human lactate dehydrogenase A (LDHA). These potent inhibitors were typically selective for LDHA over LDHB isoform (4-10 fold) and other structurally related malate dehydrogenases, MDH1 and MDH2 (>500 fold). An X-ray crystal structure of enzymatically most potent molecule bound to LDHA revealed two additional interactions associated with enhanced biochemical potency. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.11.008
• 作为产物：
  描述：

  4-(2,6-dichlorophenyl)-3-buten-2-one 在 sodium hydroxide 、 硫酸 、 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 12.5h， 生成 5-(2,6-二氯苯基)环己烷-1,3-二酮
  参考文献：
  名称：

  Antimalarial drugs. 64. Synthesis and antimalarial properties of 1-imino derivatives of 7-chloro-3-substituted-3,4-dihydro-1,9(2H,10H)-acridinediones and related structures

  摘要：

  To improve upon the activity and properties of the 3-aryl-7-chloro-3,4-dihydro-1,9(2H,10H)-acridinediones, a variety of 1-[(alkylamino)alkylene]imino derivatives (3) were prepared and shown to be highly active antimalarial agents in both rodents and primates. Among structural modifications prepared, including N-10-alkyl and C2-substituted analogs, removal of the C-9 oxygen, and introduction of an imino side chain at C-9, the imines of the N-10-H acridinediones were the most active compounds obtained. The [3-(NN-dimethylamino)propyl]imino derivative of 7-chloro-3-(2,4-dichlorophenyl)-3,4-dihydro-1,9(2H,10H)-acridinedione (9aa) proved to be highly active in advanced studies in primates.

  DOI：

  10.1021/jm00097a001

文献信息

• Aminoguanidine hydrazone derivatives, process for producing the same and drugs thereof
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06350749B1

  公开（公告）日：2002-02-26

  The present invention is to provide a compound of the formula: wherein the ring A is an optionally substituted 5- to 6-membered aromatic heterocyclic ring, the ring B an optionally substituted 5- to 6-membered aromatic homocyclic ring or an optionally substituted 5- to 6-membered aromatic heterocyclic ring, R1 is a hydrogen atom, a hydroxy group or a lower alkyl group, and n is 0 or 1, or a salt thereof, which is effective for the prevention or treatment of ischemic cardiac disease, etc., and which is useful as an agent for preventing or treating ischemic cardiac disease, etc. such as myocardial infarction, arrhythmia, etc.

  本发明提供了一种化合物的公式：其中环A是可选地取代的5至6成员芳香杂环，环B是可选地取代的5至6成员的芳香同环或可选地取代的5至6成员的芳香杂环，R1是氢原子，羟基或低烷基，n是0或1，或其盐，该盐对于预防或治疗缺血性心脏病等有效，并可作为预防或治疗缺血性心脏病等的药物，例如心肌梗死、心律失常等。
• Cinchona Squaramide‐Catalyzed Intermolecular Desymmetrization of 1,3‐Diketones Leading to Chiral 1,4‐Dihydropyridines
  作者：Maciej Dajek、Agnieszka Pruszczyńska、Krzysztof A. Konieczny、Rafał Kowalczyk

  DOI：10.1002/adsc.202000455

  日期：2020.9.8

  Addition of prochiral cyclic 1,3‐diketones to Michael acceptors applying bifunctional Cinchona‐derived squaramides resulted in chiral adducts with stereoselectivities of up to 99% ee and allowed for desymmetrization of the nucleophile. These labile hemiacetal intermediates were transformed to new 1,4‐dihydropyridines with high diastereoselectivities and no erosion of optical purity. Their further oxidation

  在使用双官能金鸡纳衍生的方酰胺的迈克尔受体上添加前手性环状1,3-二酮会导致手性加合物的立体选择性高达99％ee，并允许亲核试剂脱对称。这些不稳定的半缩醛中间体被转化为新的1,4-二氢吡啶，具有高非对映选择性，且不会破坏光学纯度。它们进一步氧化为吡啶，然后进行费舍尔吲哚化，提供了手性吡啶吲哚。
• Harnessing hypervalent iodonium ylides as carbene precursors: C–H activation of <i>N</i>-methoxybenzamides with a Rh(<scp>iii</scp>)-catalyst
  作者：Sivakalai Mayakrishnan、Masilamani Tamizmani、Naryanan Uma Maheswari

  DOI：10.1039/d0cc06038k

  日期：——

  Hypervalent iodonium ylides expeditiously generate carbenes which undergo domino intermolecular C–H activation followed by intramolecular condensation in the presence of N-methoxybenzamide as a starting material and a Rh(III)-catalyst to afford dihydrophenanthridines. KIE studies and DFT calculations were performed to substantiate the mechanistic pathway. To extend the synthetic utilisation, fluorescent

  高价碘鎓叶立德迅速生成碳烯，这些碳烯经过多米诺骨牌分子间CH活化，然后在以N-甲氧基苯甲酰胺为起始原料和Rh（III）催化剂存在下进行分子内缩合，得到二氢菲啶。进行了KIE研究和DFT计算，以证实机理途径。以延长合成利用率，荧光pyranoisocoumarins通过使用的Rh（实现III）催化围-C-H / O-H活化/环反应。
• Substituted dihydropyridines and methods of use
  申请人：Hurt Ray Clarence

  公开号：US20070112015A1

  公开（公告）日：2007-05-17

  Compounds are provided that are modulators of the C5a receptor. The compounds are substituted dihydropyridines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activtation of C5a receptors.

  提供了调节C5a受体的化合物。这些化合物是取代二氢吡啶，并可用于制药组合物、治疗涉及C5a受体病理性激活的疾病和障碍的方法。
• 1,3-环己二酮类化合物及其药物组合物和应用
  申请人：中国科学院上海药物研究所

  公开号：CN115246783A

  公开（公告）日：2022-10-28

  本发明属于药物化学和化学合成领域，具体而言，本发明涉及一种1,3‑环己二酮类化合物及其药物组合物和应用，1,3‑环己二酮类化合物的结构式如式I所示。本发明的1,3‑环己二酮类化合物不仅具有良好的水溶性和稳定性，在分子水平、细胞水平对LDHA具有较好的抑制活性，并在体内体现出抗肿瘤活性的化合物。